- Yunnan Baiyao reported a net income of 1.93 billion yuan for the first quarter of 2025.
- The company’s revenue for the same period was 10.84 billion yuan.
- Analyst ratings include 22 buy recommendations, with no hold or sell recommendations.
A look at Yunnan Baiyao Group Co., Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Yunnan Baiyao Group Co. is positioned for a positive long-term outlook based on the Smartkarma Smart Scores. With a high Dividend score of 5, investors can expect consistent and attractive dividend payouts over time. Additionally, the company receives strong scores in Growth and Resilience at 4 each, indicating a promising potential for expansion and the ability to withstand market challenges. These factors contribute to a favorable overall perception of the company’s performance.
Although Yunnan Baiyao Group Co. doesn’t score as high in Value and Momentum, with scores of 3 for both, its strong showing in Dividend, Growth, and Resilience bodes well for its future trajectory. The company’s diverse operations in manufacturing traditional Chinese medicines, pharmaceutical trading, capsules manufacturing, and hotel services provide a solid foundation for growth and stability in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
